RadCore Labs

RadCore Labs is a clinical-stage biotechnology company focused on the development of innovative radiopharmaceuticals for oncology. Based in Columbus, Ohio, and originating from The Ohio State University, the company utilizes a proprietary platform to design targeted imaging and therapeutic agents, often referred to as theranostics. Their pipeline includes candidates targeting Prostate-specific membrane antigen (PSMA) and Gastrin-releasing peptide receptor (GRPR) to address unmet needs in prostate cancer and other solid tumors. By integrating advanced radiochemistry with molecular targeting, RadCore Labs seeks to improve patient outcomes through more precise diagnosis and personalized treatment. The company aims to streamline the translation of novel radiotracers from academic research into clinical applications.